Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation
- Conditions
- Colorectal Cancer
- Interventions
- Procedure: - use of resorbable membrane SeprafilmProcedure: without resorbable barrier (seprafilm)
- Registration Number
- NCT01262417
- Lead Sponsor
- Centre Leon Berard
- Brief Summary
The purpose of this study is to evaluate the efficiency of a resorbable barrier membrane for the prevention of abdominal and peri-hepatic adhesion in patients with colorectal cancer requiring two-stage surgery for the resection of hepatic metastases.
Eligible patients will be randomly assigned to one of 2 arms:
* Seprafilm group (receiving resorbable barrier membrane during the first surgery)
* No-treatment control group (without seprafilm barrier during the first surgery)
The primary objective is to establish, in patients with colorectal cancer requiring two-stage surgery for the resection of hepatic metastases, the efficiency of a resorbable barrier membrane (Seprafilm) for limiting abdominal and peri-hepatic adhesion during the second operation.
This study is a prospective multicentric phase II, controlled, randomized and non comparative trial.
A total of 60 patients will be enrolled: 45 will receive Seprafilm whereas 15 will be assigned to the no-treatment control group. The inclusion period should be approximately 18 months. The follow up period after the second surgery will be 3 years.
- Detailed Description
The secondary objectives of the study are:
During and after the 1st surgical procedure To evaluate immediate complications (during surgery), early complications (during post-surgery hospitalization) and late complications (between 1st and 2nd surgeries) in relation with operating procedure and use of resorbable membrane.
During and after the 2nd surgical procedure
* To evaluate abdominal and peri-hepatic adhesion (at the site of the 1st surgery), with qualitative and quantitative description.
* To evaluate intestinal adhesion (in the small intestine), with quantitative description.
* To evaluate immediate complications (during surgery), early complications (during post-surgery hospitalization) and late complications (in the month following the intervention) in relation with operating procedure.
* To evaluate post-operative rehabilitation
* To assess tumour evolution in patients over a period of 3 years after the 2nd surgery.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Women and men aged ≥ 18 years
- Colorectal cancer with synchronous or metachronous hepatic metastases
- Patients requiring two-stage surgery with laparotomy for the resection of hepatic metastases
- The 2 operations should be scheduled in the same centre
- The 2 operations should be scheduled at an interval of 1 to 6 months
- Patient affiliated with social security
- Patient able to read and write French
- Written, voluntary, informed consent
- Patient with previous hepatic or biliary surgery through supra-umbilical incision (except biliary surgery with laparotomy more than 6 months previously)
- Patient with previous major surgery except colorectal surgery for resection of primitive tumour
- Metastasis removable in one surgical procedure
- Non resectable metastasis
- Follow-up impossible for social, geographical, familial or psychological reasons
- Patient deprived of freedom
- Patient enrolled in another experimental surgery trial
- Pregnant or lactating woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description - Seprafilm group - use of resorbable membrane Seprafilm patients receiving resorbable barrier membrane during the first surgery - No-treatment control group without resorbable barrier (seprafilm) patients without seprafilm barrier during the first surgery
- Primary Outcome Measures
Name Time Method abdominal and peri-hepatic adhesion during the second operation Time to liberate liver (t0: incision and t1: liberation)
- Secondary Outcome Measures
Name Time Method immediate complications during the first surgical procedure in relation with operating procedure and use of resorbable membrane during the surgery early complications (after the 1st surgical procedure)in relation with operating procedure and use of resorbable membrane during post-surgery hospitalization late complications (after the 1st surgical procedure)in relation with operating procedure and use of resorbable membrane between 1st and 2nd surgeries (2 operations should be scheduled at an interval of 1 to 6 months) abdominal and peri-hepatic adhesion (at the site of the 1st surgery), with qualitative and quantitative description at the beginning of the 2nd surgical procedure intestinal adhesion (in the small intestine), with quantitative description at the beginning of the second surgical procedure immediate complications in relation with operating procedure. during the 2nd surgical procedure early complications (after 2ng operation) in relation with operating procedure. during post-surgery hospitalization late complications in relation with operating procedure. in the month following the 2nd intervention post-operative rehabilitation during post-surgery hospitalization tumour evolution in patients over a period of 3 years after the 2nd surgery
Trial Locations
- Locations (17)
Institut Bergonié
🇫🇷Bordeaux, France
Hôpital Antoine Béclère
🇫🇷Clamart, France
CHU Clermont Ferrand
🇫🇷Clermont Ferrand, France
Centre Hospitalier Lyon Sud
🇫🇷Lyon, France
CHU Grenoble
🇫🇷Grenoble, France
Centre Léon Bérard
🇫🇷Lyon, France
Hôpital de La Croix Rousse
🇫🇷Lyon, France
CHU La conception
🇫🇷Marseille, France
Institut Paoli Calmettes
🇫🇷Marseille, France
Hôpital de Brabois CHU
🇫🇷Nancy, France
CHU Nice-Hôpital de l'Archet II
🇫🇷Nice, France
Hôpital Cochin
🇫🇷Paris, France
Hôpital Beaujon
🇫🇷Clichy, France
Centre Val d'Aurelle Paul Lamarque
🇫🇷Montpellier, France
Centre Alexis Vautrin
🇫🇷Nancy, France
Hôpital Charles Nicolle - CHU Rouen
🇫🇷Rouen, France
Institut Gustave Roussy
🇫🇷Villejuif, France